Objective. Abnormal function of high-density lipoprotein (HDL) has been implicated as a potential mechanism for the increased incidence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA). This study was undertaken to evaluate changes in HDL function and HDL-associated proteins over 2 years of follow-up in patients with early RA receiving either methotrexate (MTX) monotherapy, MTX 1 etanercept (ETN) combination therapy, or MTX 1 sulfasalazine (SSZ) 1 hydroxychloroquine (HCQ) triple therapy in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.
Patients with rheumatoid arthritis (RA) experience a significantly increased frequency of cardiovascular (CV) morbidity and mortality when compared to the general population, with, in particular, a 48% increased risk of incident CV disease (1) (2) (3) . Augmented levels of systemic inflammation resulting from active RA have been strongly associated with the occurrence of death attributable to CV events as well as with subclinical atherosclerosis in RA patients (4, 5) . Results of epidemiologic studies have suggested the potential beneficial effects of disease-modifying antirheumatic drug (DMARD) therapy on CV-related mortality in RA patients (6, 7) . However, the mechanisms of CV-protective effects are largely unclear. Better understanding of the interaction between systemic inflammation and the pathophysiologic development of vascular complications in RA is needed for adequate CV risk assessment and initiation of targeted prevention strategies.
High-density lipoproteins (HDLs) are complex particles composed of phospholipids, cholesterol, and multiple HDL-associated proteins that actively participate in the antioxidant and antiatherogenic functions of these particles (8, 9) . Epidemiologic studies in the general population have consistently shown that higher HDL cholesterol levels are associated with a lower risk of CV disease (10, 11) . However, significant research has suggested that the function of the HDL particle, including its ability to promote cholesterol efflux and inhibit low-density lipoprotein (LDL) oxidation, may be more important to CV risk than its cholesterol content as measured by the HDL cholesterol level (12) (13) (14) . Recent large clinical trials assessing the efficacy of cholesterol ester transfer protein inhibitors, which increase HDL cholesterol levels but have inconclusive effects on HDL function, did not show a therapeutic benefit on CV outcomes (15, 16) , thus strengthening the hypothesis that the function, rather than the cholesterol content, is important to the antiatherogenic role of HDL.
Our prior studies have shown that high levels of inflammation in patients with active RA are associated with abnormal HDL function and alterations in multiple HDLassociated proteins (8, 17, 18) (Figure 1 ). In the current study, we evaluated whether treatment of RA can improve the antioxidant function of HDL and "reverse" these protein changes. We studied the effect of treatment with either methotrexate (MTX) monotherapy, MTX 1 etanercept (ETA) combination therapy, or MTX 1 sulfasalazine (SSZ) 1 hydroxychloroquine (HCQ) triple therapy on HDL function and on the levels of several HDL-associated proteins in patients with early RA participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.
PATIENTS AND METHODS
Study design. The TEAR trial was a 2-year randomized clinical trial of 755 patients with early RA who had minimal prior use of DMARDs and who were initially randomized to receive MTX monotherapy (titrated to 20 mg/week), combination therapy with MTX 1 ETA, or triple therapy with MTX 1 SSZ 1 HCQ (19) . Patients were allowed to have previously received treatment with leflunomide, HCQ, or SSZ for no more than 2 months, and to have previously received a total dose of #40 mg of MTX (19) . After 6 months of treatment, participants receiving MTX monotherapy who did not achieve low disease activity (defined according to change in the Disease Activity Score in 28 joints [DAS28] [20] and an erythrocyte sedimentation rate [ESR] of ,3.2 mm/hour) were "stepped up" to receive either MTX 1 ETA combination therapy or triple therapy, as determined by a baseline randomization algorithm. All treatment arms included a matching placebo treatment. No further protocol changes in treatment assignment occurred after 24 weeks of the study.
All patients met the American College of Rheumatology (ACR) 1987 classification criteria for RA (21) and were serologically positive for signs of rheumatic disease or had evidence of erosive disease on baseline radiographs of the hands or feet. Lowdose prednisone (#10 mg/day) was allowed in the study but had to be maintained at a stable dosage for at least 2 weeks prior to Figure 1 . High-density lipoprotein (HDL) is a particle composed of multiple associated proteins, which perform the antiinflammatory and antiatherogenic functions of HDL. A normal, antiinflammatory HDL particle (depicted in dark green) has several major associated proteins, including paraoxonase 1 (PON-1), apolipoprotein A-I (Apo A-I), lecithin cholesterol acyl transferase (LCAT), and platelet-activating factor acetylhydrolase (PAF-AH). In the setting of active inflammation (depicted in red), such as in active rheumatoid arthritis (RA), HDL may become nonprotective, and even proinflammatory, by alteration in the level and function of several proteins. Protein changes shown include 1) displacement of Apo A-I by serum amyloid A (SAA), 2) increased production of haptoglobin (Hp) in HDL, which binds Apo A-I, blocking LCAT activation, and 3) decreased PON-1 activity via oxidative modification of PON-1 by the enzyme myeloperoxidase (MPO).
screening and throughout the trial. Full results of the clinical trial have been previously published (19) . Patients provided consent for participation in the TEAR trial and, separately, for the biorepository substudy. All patients for whom samples were available and who gave their signed consent for the TEAR biorepository study were included in the current analysis.
Laboratory testing. Serum samples obtained in a nonfasting state from a total of 550 patients participating in the TEAR biorepository study were available for analysis. Serum samples were collected over 2 years of follow-up, at 0, 24, 48, and 102 weeks, and stored at 2808C until analyzed. Samples from individual patients at all time points were run together for each of the HDL function assays. Internal controls were used for the paraoxonase 1 (PON-1) and cell-free assays, and enzyme-linked immunosorbent assays (ELISAs) were normalized between runs using 4 control samples included with each plate. C-reactive protein (CRP) levels (in mg/liter) were measured at the Clinical and Epidemiological Research Laboratory at Children's Hospital in Boston, using a high-sensitivity immunoturbidimetric assay on a Hitachi 917 autoanalyzer (Roche Diagnostics), with the use of reagents and calibrators from Denka Seiken. The ESR, 28-tender joint and 28-swollen joint counts, and the patient's and physician's global assessments of disease activity were assessed locally at each site, and the DAS28-ESR was calculated.
Determination of PON-1 activity. PON-1 activity was quantified as previously described (22) , with use of paraoxon (purchased from Sigma) as the substrate and by measuring the increase in the absorbance at 405 nm due to the formation of 4-nitrophenol over a period of 12 minutes (at 20-second intervals). Paraoxon was further purified using chloroform extraction. A unit of PON-1 activity was defined as the formation of 1 nmole of 4-ntirophenol per minute per milliliter of sample used.
Evaluation of HDL antioxidant function. Cell-free assays were carried out using a modification of a previously published method (23) and using LDL as the fluorescenceinducing agent. Control LDL was prepared as described previously (23) , and HDL-containing supernatants were isolated using Dextran bead precipitation.
To determine the antiinflammatory properties of HDL, the change in fluorescence intensity as a result of the oxidation of dihydrodichlorofluorescein (DCFH) in incubations with a standard LDL, in the absence or presence of the test HDL, was assessed. Results are reported as the HDL inflammatory index (HII). Briefly, 25 ml of LDL cholesterol (100 mg/ml) was mixed with 125 ml of test HDL (100 mg HDL cholesterol/ml) in black, flat-bottomed polystyrene microtiter plates, followed by incubation at 378C with rotation for 30 minutes. Thereafter, 25 ml of DCFH solution (0.2 mg/ml) was added to each well, and the supernatants were mixed and incubated at 378C for 1 hour with rotation. Fluorescence was determined with a plate reader (Spectra Max, Gemini XS; Molecular Devices) at an excitation wavelength of 485 nm, emission wavelength of 530 nm, and cutoff of 515 nm, with the photomultiplier sensitivity set at medium. Values for intra-and interassay variability were a mean 6 SD 0.5 6 0.37% and 3.0 6 1.7%, respectively (24) .
Determination of HDL-associated haptoglobin (Hp) and apolipoprotein A-I (Apo A-I). Assays for HDL-associated Hp and HDL-associated Apo A-I were modifications of previously published methods (8, 17, 25) . Briefly, 96-well microtiter plates were precoated with a human HDL antibody at 1:333 dilution overnight at 48C. Plates were washed and blocked with 1% nonfat milk in 13 phosphate buffered saline for 60 minutes at room temperature. After washing, the plates were coated with individual plasma samples (diluted at 1:4,000 for HDLassociated Hp and diluted at 1:80,000 for HDL-associated Apo A-I) and incubated for 60 minutes at room temperature. Plates were next washed and incubated at room temperature for 60 minutes with a horseradish peroxidase (HRP)-conjugated antibody for Hp at 1:8,000 dilution or an HRP-conjugated antibody for Apo A-I at 1:4,000 dilution. Following incubation with tetramethylbenzidine (TMB) solution for 20 minutes, HRP activity was measured at an optical density of 450 nm. A protein standard for each assay was run by coating a set of standard wells with an Hp antibody at 1:200 dilution or Apo A-1 antibody at 1:500 dilution, followed by blocking with 50 mM Tris, 0.14M NaCl, 1% bovine serum albumin (BSA) for 60 minutes at room temperature. After washing, the wells were coated with a Protein Calibrator using serial dilutions. The remainder of the assays were performed as described above for the serum samples. All antibodies were purchased from Genway Biotech.
ELISA for detection of myeloperoxidase (MPO). An MPO ELISA was performed using a kit from Aviscera Bioscience. Briefly, 96-well microtiter plates were precoated with an MPO-capturing antibody at 1:100 dilution overnight at 48C. Plates were washed and blocked with 50 mM Tris, 0.14M NaCl, 1% BSA overnight at 48C. After washing, the plates were coated with individual plasma samples diluted at 1:10 and incubated for 2 hours at room temperature. Samples were aspirated from the plates, which were then incubated for 2 hours at room temperature with 1:100 dilution of detection antibody followed by incubation with 1:200 dilution of streptavidin-HRP for 60 minutes at room temperature. HRP activity was measured at an optical density of 450 nm after 20 minutes of incubation of the plates with TMB solution.
Statistical analysis. Clinical characteristics and biomarkers were compared between treatment groups using one-way analysis of variance for continuous variables and chi-square test for categorical variables. To determine the relative contribution of RA treatments, RA disease activity/systemic inflammation, and other patient characteristics to changes in HDL function and HDL-associated proteins over time, repeated-measures analysis with linear mixed-effects models (26) were used to model the within-subject covariance over time. Measures of disease activity/ inflammation and HDL function/HDL-associated proteins at 4 time points were included in the models as fixed effects. Separate models were constructed for each HDL outcome (HII, PON-1 activity, HDL-associated Apo A-I levels, HDL-associated Hp levels, and MPO levels), and for each measure of disease activity/ inflammation (ESR, CRP levels, or the DAS28). Other fixedeffects patient covariates included treatment assignment at each time point, age, sex, race, RA disease duration, baseline body mass index (BMI), current smoking status (measured using the baseline cotinine levels in the blood), statin use, prednisone use, diabetes, and presence of CV disease. Log transformation was performed on all outcome measurements. All statistical testing was 2-sided with a significance threshold of a 5 0.05. Statistical analyses were carried out using SAS version 9.3 (SAS Institute).
RESULTS
Demographic and clinical characteristics of the patients with RA. The baseline demographic and clinical characteristics of the TEAR patients participating in the 48 CHARLES-SCHOEMAN ET AL biorepository substudy whose samples were available for the current analysis are shown in Table 1 . The population studied was very similar in demographics to the main TEAR trial population as well as the substudy populations analyzed previously (19, 27, 28) . No significant differences between treatment arms were observed in important demographic and clinical variables, including age, sex, race, BMI, and smoking status. More than 84% of patients in each group were rheumatoid factor positive, and the mean disease duration was ,4.3 months in all groups. Patients had very active arthritis at baseline, with a mean baseline DAS28 of $5.5 and elevated markers of inflammation (CRP level and ESR) in all treatment groups. The proportion of patients with comorbidities, including diabetes and known CV disease, was similar between the groups at baseline, as was the use of prednisone and statins. No differences in baseline HDL function markers or traditional cholesterol levels were observed. Changes in HDL function and associated proteins over the 2-year follow-up. The antioxidant capacity of HDL (measured as the HII) and the levels of PON-1 activity, HDL-associated Hp, HDL-associated Apo A-I, and MPO were evaluated at 4 time points over the 2-year follow-up in each of the 5 TEAR treatment groups (Table 2) . Overall, small mean differences in the HDL function markers were noted between the treatment groups over time, although none of the differences were significant over the long-term follow-up, with the exception of the levels of HDL-associated Hp at 102 weeks, which were lowest in the triple therapy and stepup triple therapy groups. MPO levels were significantly different between treatment groups at 24 weeks, with the lowest levels seen in the triple therapy group, although these differences did not remain significant after 102 weeks of treatment.
Association of changes in HDL function with changes in RA disease activity and systemic inflammation. Several modest, but significant, correlations were noted between changes in the CRP level and changes in HDL function and associated proteins over the trial follow-up period. Specifically, we noted positive associations of changes in the CRP level with changes in the Step-up MTX 1 ETA (n 5 124)
Step-up triple therapy (n 5 58) Step-up MTX 1 ETA (n 5 124)
Step-up triple therapy (n 5 58) P HII and HDL-associated Hp levels both over the short term (baseline to 24 weeks) and over the long-term (baseline to 102 weeks) (r 5 0.12-0.26; each P , 0.001).
Decreases in the CRP level in the treatment groups over time were associated with decreases in the HII and HDL-associated Hp levels. In contrast, consistently negative associations were noted between changes in the CRP level and changes in PON-1 activity and HDLassociated Apo A-I levels, although these changes were of more modest magnitude in univariate analysis (maximum r 5 20.15 for the correlation of percentage change in the CRP level with percentage change in the HDLassociated Apo A-I levels from 24 to 102 weeks; P 5 0.0004). These data suggest that there is a potential association between decreases in inflammation and increases in PON-1 activity and HDL-associated Apo A-I levels.
Determinants of long-term changes in HDL function and associated proteins in the TEAR cohort. In order to determine the relative contribution of RA disease activity, RA treatments, and other patient characteristics to changes in HDL function and associated proteins in the TEAR cohort over time, repeated-measures analyses with mixed-effects linear models were performed. These models included patient characteristics as well as disease activity and treatment data from all 4 time points over the 2 years of follow-up. In all 3 models tested, all of which were controlled for treatment group, age, sex, race, disease duration, BMI, smoking status, statin use, prednisone use, presence of diabetes at baseline, and presence of CV disease at baseline, we found that measures of RA disease activity and inflammation (the CRP level, the ESR, and the DAS28) were consistently associated with improvements in the HDL function profile, including 1) decreases in the HII, HDL-associated Hp levels, and MPO levels, and 2) increases in PON-1 activity and HDL-associated Apo A-I levels (Tables 3-5). Most of these relationships were statistically significant in the models, with the exception of MPO levels in the models using the CRP level or ESR as the disease activity measure (P 5 0.07 and P 5 0.09, respectively), and the levels of PON-1 activity in the models using the ESR or DAS28 (P 5 0.13 and P 5 0.10, respectively) ( Tables 3-5) .
Treatment assignment was not consistently associated with changes in any of the HDL function profile markers. However, triple therapy was significantly associated with a decrease in the HII, consistent with improvement in the overall antioxidant function of HDL, when compared to MTX monotherapy in all multivariate Table 3 for other definitions). models using the CRP level, ESR, or DAS28 as the measure of RA activity (P 5 0.01-0.02). Triple therapy was also associated with a modest improvement in the HII compared to combination therapy with MTX 1 ETA (P 5 0.05-0.07). Moreover, triple therapy was associated with a significant decrease in HDL-associated Hp levels as compared to combination therapy with MTX 1 ETA (P 5 0.02-0.04 in all models) and as compared to MTX monotherapy (P 5 0.04), in the DAS28 model (Tables  3-5) . Table 3 shows results from the mixed-effects linear models of associations with changes in the HII, PON-1 activity, and levels of HDL-associated Hp, HDLassociated Apo A-I, and MPO using the CRP level as the disease activity covariate. Decreases in the CRP level over time were associated with significant decreases in the HII and HDL-associated Hp levels. Conversely, a decrease in the CRP level was associated with significant increases in PON-1 activity and HDL-associated Apo A-I levels. Specifically, a 10-unit decrease in the CRP level was associated with a 2.34% decrease in the HII, a 3.53% decrease in the levels of HDL-associated Hp, a 3.42% increase in PON-1 activity, and an 8.74% increase in the levels of HDL-associated Apo A-I. A strong trend in the percentage change in MPO levels was also observed over time, decreasing by 1.91% per 10-unit decrease in the CRP level (P 5 0.07).
Use of triple therapy over time was associated with a lower HII, since the HII decreased by 11.78% in the triple therapy group compared to the MTX monotherapy group (P 5 0.02), while the HII increased by 9.69% in patients receiving combination therapy with MTX 1 ETA compared to those receiving triple therapy (P 5 0.07). Triple therapy was also associated with significantly lower levels of HDL-associated Hp over time, since patients receiving MTX 1 ETA combination therapy showed an increase of 10.63% in HDL-associated Hp levels compared to patients receiving triple therapy (P 5 0.02). These data suggest a potential beneficial effect of triple therapy with MTX 1 SSZ 1 HCQ on the HDL particle. Similar effects of triple therapy, as compared to MTX monotherapy and MTX 1 ETA combination therapy, were observed in the models in which RA disease activity was measured using the ESR or the DAS28 (Tables 4 and 5) .
Several patient characteristics were associated with changes in the HDL function profile over time in the mixed-effects models (Tables 3-5) . Female sex, compared to male sex, was associated with lower MPO levels, Table 3 for other definitions).
CHARLES-SCHOEMAN ET AL
with female patients showing a decrease in MPO of as much as 16% (P , 0.01 in all models). Higher BMI was associated with a worse HDL function profile, including a higher HII (worse antioxidant capacity), higher levels of HDL-associated Hp, and lower levels of HDLassociated Apo A-I (P # 0.02 in all models). Smoking was also associated with worse HDL function, including a higher HII and lower levels of HDL-associated Apo A-I (P 5 0.04-0.09 in all models). African American race was associated with higher PON-1 activity (increases over time ranging from 44.72% to 47.05%; P , 0.01 in all models) and also associated with higher MPO levels (increases of .37%; P , 0.01 in all models) when compared to that in Caucasians. Patients of African American race had a lower HII (P 5 0.02-0.03 in all models) compared to Caucasians and those of other races. Furthermore, in all models, strong trends in HDLassociated Hp levels, which were found to be lower in African Americans compared to Caucasians and other races, and in HDL-associated Apo A-I levels, which were found to be higher in African Americans compared to Caucasians and other races, were also observed (P 5 0.02-0.13).
Finally, use of statins at baseline was modestly associated with a lower HII over time (P 5 0.09-0.15 in all models). This finding is consistent with our observations of better HDL antioxidant function over the 2-year trial follow-up.
DISCUSSION
Investigators have previously suggested that HDL may have evolved as part of the innate immune response, which uses rapid induction of an oxidative state as a means of combating bacteria and viruses (29) . In the absence of acute or chronic inflammation, HDL is an antiinflammatory, protective particle in mice, rabbits, and humans. However, with onset of a systemic inflammatory state, HDL becomes proinflammatory and nonprotective, in part due to alteration in the level and function of several of its associated proteins (9, 29, 30) .
Under normal conditions, HDL inhibits oxidation of LDL to an inflammatory form, which promotes the development of atherosclerosis, and HDL also promotes cholesterol efflux from peripheral tissues, including the artery wall (12, 31) . During systemic inflammation, these functions of HDL are impaired by oxidative modification of the HDL particle, including its associated protein, PON-1 (32) . This process occurs in part via prooxidant enzymes such as MPO, and promotes the development of a dysfunctional, even "prooxidant" particle (33) (Figure  1 ). Additional changes in the protein cargo of HDL that may occur include increases in the levels of acute-phase proteins such as serum amyloid A (SAA), fibrinogen, and Hp, as well as decreases in the levels of the major HDLassociated protein Apo A-I (8, 30) (Figure 1) .
Active RA has been associated with abnormal HDL function and structure and a markedly increased risk of CV events (3, 4, 8, 17) . In particular, previous findings have suggested that both the cholesterol efflux function and the antioxidant function of HDL are impaired in patients with high RA disease activity, and that both functions are correlated (17, 18) . Impaired cholesterol efflux by HDL and lower antioxidant capacity have also been associated with CV events and death in the general population (12) (13) (14) . Therefore, impairment in HDL function has been proposed as a mechanism by which active RA increases the CV risk. In the current study, we evaluated whether improvement in the management of disease activity in patients with RA in the TEAR trial could "reverse" the deleterious effects of inflammation on the HDL particle. We examined the overall antioxidant function of HDL as well as a panel of 4 HDL-associated proteins.
A major strength of this study was the robust repeated-measures analyses, which were controlled for RA treatments as well as other patient characteristics and in which data from 4 different time points over 2 years of follow-up were incorporated to evaluate potential associations between changes in RA disease activity/ inflammation and changes in the HDL function profile. Separate models were analyzed for each measure of RA disease activity, including the CRP level, the ESR, and the DAS28, and each model yielded very similar results. Improvement in RA disease activity was associated with improvement in the HDL function profile, including decreases in the HII (representing improved antioxidant capacity), decreases in the levels of HDL-associated Hp and MPO, and increases in PON-1 activity and in the levels of HDL-associated Apo A-I.
Studies of other DMARDs in RA patients have also shown improvement in select markers of HDL function. RA patients with an inadequate response to MTX who were treated with tocilizumab (n 5 69) experienced significant increases in PON-1 activity and decreases in the levels of HDL-associated SAA compared to those receiving placebo (n 5 63) (34) . Treatment with tocilizumab also decreased the levels of inflammation as measured by the CRP level; however, specific relationships between changes in RA disease activity and changes in PON-1 activity or HDL-associated SAA levels were not reported (34) . Similarly, in another study of tofacitinib treatment in a small cohort of patients with active RA (n 5 36), the levels of HDL-associated SAA decreased after treatment (P 5 0.06) (35) . Popa et al reported that treatment of RA patients with infliximab improved both PON-1 activity (in 45 patients) and the antioxidative capacity of HDL (in 15 patients), and those authors also described modest but significant correlations between PON-1 activity and the ESR or DAS28 at baseline and after 2 weeks of therapy (36) . Finally, Raterman et al studied the protein cargo of HDL using mass spectrometry in 6 RA patients with an excellent response to rituximab, as compared to 6 RA patients who were nonresponders (37) . Those RA patients with excellent responses to rituximab showed a significant decrease in the levels of HDLassociated SAA, a change that was not observed in the nonresponders (37) .
The current study is the first large randomized, controlled clinical trial of MTX monotherapy in comparison with combination therapy or triple therapy, utilizing both biologic and nonbiologic agents, to examine changes in a panel of HDL function markers over a long-term, 2-year follow-up. Improvement in RA disease activity was consistently associated with improvement in the HDL function panel in all multivariate models. Associations were also noted between select markers of HDL function and several patient characteristics, including type of treatment. Unexpectedly, triple therapy was associated with improved antioxidant function of HDL over time, as measured by a lower HII when compared to that in patients receiving either MTX monotherapy or combination therapy with MTX 1 ETA. In all models, triple therapy was also associated with lower HDL-associated Hp levels over time as compared to that in the MTX 1 ETA combination therapy group, and was associated with a trend toward lower HDL-associated Hp levels as compared to the MTX monotherapy group. The clinical significance of lower levels of HDL-associated Hp over time in RA patients warrants further study.
Previous observational work has suggested that HCQ is associated with a favorable lipid profile in RA patients (38) . Results from our recent study confirmed this observation, demonstrating that triple therapy was associated with lower LDL cholesterol levels over the long-term follow-up in the TEAR trial (27) . Interestingly, a small study by Breton et al in non-RA patients (n 5 50) found that lower LDL cholesterol levels were predictors of better antioxidant function of HDL, as measured using a similar assay as that used in the current study (39) . While these data suggest that triple therapy, and perhaps HCQ, may lead to better antioxidant function of HDL by lowering the levels of LDL cholesterol, further mechanistic work to understand this relationship is needed. In addition, the association of triple therapy with lower HDL-associated Hp levels warrants confirmation in additional studies.
Several other patient characteristics were significantly associated with HDL function over the long-term follow-up in the TEAR trial. Many of these patient characteristics, such as smoking, race, and BMI, showed similar effects on HDL function in RA patients, as has been previously reported in the general population. For example, a status of current smoking was associated with lower levels of HDL-associated Apo A-I, by ;30%, as well as a higher HII in all models. These results are consistent with the findings in an earlier study by Berg et al, which demonstrated significantly lower levels of Apo A-I in smokers compared to nonsmokers among non-RA patients (40) . Another study has shown that cigarette smoke oxidatively modifies the HDL particle and is associated with decreased HDL function (41) .
African American race in the TEAR cohort was associated with significantly higher PON-1 activity, a lower HII, and a trend toward higher levels of HDL-associated Apo A-I and lower levels of HDL-associated Hp compared to patients of Caucasian race in all models. A study of a non-RA population of African Americans from the South previously showed that African Americans had higher PON-1 activity compared to Caucasians (42) . Moreover, one study found that Apo A-I levels were significantly higher in non-RA African Americans compared to non-RA Caucasians (43) . Furthermore, MPO levels were consistently higher in African Americans compared to Caucasians in the TEAR trial, similar to the results of the Dallas Heart Study in non-RA patients (44) .
Obesity has previously been linked to impaired HDL function in non-RA patients (45) . In the current study, a higher BMI was consistently associated with a worse HDL function profile, including a higher HII, higher levels of HDL-associated Hp, and lower levels of HDLassociated Apo A-I. Previous findings have suggested that statins have beneficial effects on the antioxidant function of HDL (13, 24) . In the present study, a strong trend toward better HDL antioxidant function was observed in patients who received statins compared to patients who did not receive statins. In summary, our findings reinforce the importance of both RA-specific and nonspecific patient factors to HDL function over the long-term follow-up.
Only a few CV events occurred during the 2-year TEAR trial, with 3 deaths that were attributed to CV disorders (general [unattended death], coronary heart failure, and ventricular septal defect) (19) . A CV adjudication process was not used during the study. While associations between the HDL function markers and CV events could not be assessed for these reasons, data on the general population suggest that there are strong links between HDL function and CV risk (12) (13) (14) . In particular, impaired cholesterol efflux by HDL has been associated with CV events, 54 CHARLES-SCHOEMAN ET AL and in a study by Ansell et al, they observed worse antioxidant function of HDL in patients with coronary heart disease compared to matched controls, even in patients with high HDL cholesterol levels (13). Bhattacharyya et al found that PON-1 activity was significantly lower in .1,100 patients with CV disease compared to controls without CV disease (14) . Lower plasma PON-1 activity has also been significantly associated with CV risk, as assessed by the presence of carotid plaque, in a cohort of 168 RA patients (22) . Finally, multiple studies have shown strong associations of MPO levels with a risk of CV disease in non-RA patients (46) (47) (48) .
There are some limitations to the current work. The study describes a population of patients with very early RA who had high disease activity at baseline, who were primarily seropositive, and who had not received prior treatment with DMARDs. These results may not be generalizable to RA patients with more established disease or those with lower levels of disease activity. Additional studies are warranted.
In addition, data on use of prednisone and statins were only available at the baseline visit for the TEAR patients. It is possible that changes in these medications over the 2-year follow-up could have affected the HDL function assays in the study. However, it is unlikely that these effects would be of significant magnitude to alter the strong and consistent relationships between RA disease activity and the multiple assays of HDL function described in the several models tested. Moreover, the use of statins at baseline was associated with the expected trend toward better HDL antioxidant function (13, 24) . Finally, information on use of additional medications that could have affected HDL function, including non-statin cholesterollowering medications and supplements, was not available for the analyses.
In summary, the results of the present study demonstrate that improvement in RA disease activity, whether measured by the DAS28, the ESR, or the CRP level, in patients with early RA treated in the TEAR trial was associated with an improvement in the HDL function profile, including decreases in the HII (indicative of improvement in the antioxidant capacity of HDL), decreases in the levels of HDL-associated Hp and MPO, and increases in PON-1 activity and the levels of HDL-associated Apo A-I. Growing epidemiologic work suggests that aggressive treatment of active RA decreases the incidence of CV morbidity and mortality, despite the variable increases in traditional cholesterol levels (7, (49) (50) (51) . The current data provide a potential mechanism for the beneficial effects of improved disease control on CV risk by improvement in HDL function. The identification of specific mechanisms linking RA disease activity to CV risk is particularly important in patients with RA whose disease remains active despite currently available treatments. Better understanding of these mechanisms may lead to development of alternative, targeted therapeutics for prevention of CV disease in these high-risk patients.
